SHH and breast cancer: Current evidence suggests that Hh signaling in breast cancer overall, and TNBC specifically, is not mutation‐driven; infrequent somatic mutations in SHH, PTCH, and GLI177, 78, 79 have been reported; however, these findings have not been replicated in other studies 80, 81.